Evolution of the Average Target: Omeros Corporation

Evolution of the Target Price: Omeros Corporation

Changes in Analyst Recommendations: Omeros Corporation

5b9c0313a522c852.L8asSs6eLDpns-A1oQ60MY6K9_DdkHjLoGwBUSFjtsE.Gv6VLKqvaAg44rd-_mL-QeLomImMyA-H6i9QEFES0adFh4ENodRADSTd2A~88e7de0d7f7c70dd34a29e6df7270507
25-10-15 Omeros Shares Surge Pre-Bell After Asset Purchase, License Deal With Novo Nordisk MT
25-06-10 HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target MT
23-03-15 UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating MT
22-12-08 UBS Downgrades Omeros to Neutral From Buy, Adjusts Price Target to $2 From $12 MT
22-11-09 BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target is $3 MT
22-06-08 BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target MT
22-01-18 Cantor Fitzgerald Adjusts Omeros' Price Target to $20 From $34, Reiterates Overweight Rating MT
21-10-19 OMEROS : HC Wainwright Adjusts Price Target on Omeros to $12 From $19, Maintains Buy Rating MT
21-10-15 OMEROS : UBS Adjusts Price Target on Omeros to $13 From $25 on Drug Filing Deficiencies, Maintains Buy Rating MT
21-10-11 OMEROS : Wedbush Suspended Coverage on Omeros MT
21-10-08 OMEROS : JPMorgan Downgrades Omeros to Underweight from Neutral MT
21-10-06 OMEROS : HC Wainwright Adjusts Omeros' Price Target to $19 from $32, Keeps Buy Rating MT
21-10-04 OMEROS : Maxim Downgrades Omeros to Hold from Buy MT
21-10-01 OMEROS : Wedbush Downgrades Omeros to Underperform From Neutral, Lowers PT to $5 From $18 After FDA Delays PDUFA For Narsoplimab MT
21-10-01 OMEROS : Maxim Group Downgrades Omeros to Hold From Buy MT
21-09-27 OMEROS : JPMorgan Starts Omeros at Neutral With $15 Price Target MT
21-06-18 OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target MT
21-04-26 OMEROS : HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy Rating MT
21-02-01 OMEROS : UBS Starts Omeros at Buy With $25 Price Target MT
21-01-20 OMEROS : HC Wainwright Adjusts Omeros' Price Target to $34 from $31, Keeps Buy Rating MT
21-01-20 OMEROS : Wedbush Adjusts Omeros' Price Target to $18 From $13, Maintains Neutral Rating MT
20-12-04 OMEROS : Maxim Adjusts Omeros' Price Target to $25 from $20, Keeps Buy Rating MT
20-11-17 OMEROS : Wedbush Adjusts Omeros' Price Target to $13 From $12, Maintains Neutral Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- +357.93%
+8.05%
+46.39%
+36.71%
+101.96%
+50.93%
+42.87%
-7.77%
+31.9%
-14.59%
Average +65.44%
Weighted average by Cap. +34.39%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
8.735USD
Average target price
40.00USD
Spread / Average Target
+357.93%
High Price Target
40.00USD
Spread / Highest target
+357.93%
Low Price Target
40.00USD
Spread / Lowest Target
+357.93%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

HC Wainwright
UBS
BofA Securities
Cantor Fitzgerald
Wedbush
JPMorgan Chase
Maxim
WBB Securities
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
8.735USD
Average target price
40.00USD
Spread / Average Target
+357.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock
  4. Consensus Omeros Corporation
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!